Cost-effectiveness of alternative treatments for women with osteoporosis in Canada

Current Medical Research and Opinion

Volumn 22, Issue 7, 2006, Pages 1425-1436

  Goeree, Ron ^a,b,c   Blackhouse, Gord ^a,b   Adachi, Jonathan ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^c ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Bisphosphonates; Canada; Cost utility analysis; Osteoporosis; Raloxifene

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; RALOXIFENE; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BREAST CANCER; CANADA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; ISCHEMIC HEART DISEASE; OSTEOPOROSIS; POSTMENOPAUSE; RISK FACTOR; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; CANADA; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; ETIDRONIC ACID; FEMALE; HUMANS; MARKOV CHAINS; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE;

EID: 33746163168     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X115568     Document Type: Article

References (82)

1. Hanley DA, Josse RG. Introduction. In: Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada [special supplement]. Can Med Assoc J 1996;155:921-3
2. Osteoporosis Canada; www.osteoporosis.ca. 2006
3. National Institute of Health Osteoporosis and Related Bone Diseases - National Resource Centre; www.osteo.org. 2006
4. National Osteoporosis Foundation; www.nof.org/osteoporosis. 2006
5. Goeree R, O'Brien B, Pettitt D, et al. An assessment of the burden of illness due to osteoporosis in Canada. J Soc Obstet Gynecol 1996;18(Suppl July 15):15-24
6. Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the national osteoporosis foundation. J Bone Miner Res 1997;12:24-35
7. Phillilps S, Fox N, Jacobs J, et al. The direct medical costs of osteoporosis for American women aged 45 and older, 1986. Bone 1988;9:271-9
8. National Institute of Health Osteoporosis and Related Bone Diseases - National Resource Centre; www.osteo.org. 2006
9. National Osteoporosis Foundation; www.nof.org/osteoporosis. 2006
10. Riggs BL, Melton III LJ. The world wide problem of osteoporosis: insights afforded by epidemiology. Bone 1995;17:505S-11S
11. National Institute of Health Osteoporosis and Related Bone Diseases - National Resource Centre; www.osteo.org. 2006
12. National Osteoporosis Foundation; www.nof.org/osteoporosis. 2006
13. National Institute of Health Osteoporosis and Related Bone Diseases - National Resource Centre; www.osteo.org. 2006
14. National Osteoporosis Foundation; www.nof.org/osteoporosis. 2006
15. Cooper C, Atkinson EJ, Jacobsen SJ, et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137:1001-5
16. Cauley JA, Thompson DE, Ensrud KC, et al. Risk of mortality following clinical fractures. Osteoporosis Int 2000;11(7):556-61
17. Josse RG. Osteoporosis. A modern plague: widespread, expensive and too often deadly. Can Pharm J 1989;122:460-8
18. Eddy DM, Johnston CC, Cummings SR, et al. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporosis Int 1998;8 (Suppl. 4):S1-S88
19. Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. New Engl J Med 1980;303:1195-8
20. Grady D, Rubin S, Pettitt DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-36
21. Kiel DP, Felson DT, Anderson JJ, et al. Hip fractures and the use of estrogens in postmenopausal women. The Framingham Study. New Engl J Med 1987;317:1169-74
22. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy in older women. Ann Intern Med 1995;122:9-16
23. van Staa TP, Abenhaim L, Cooper C. Use of cyclical etidronate and prevention of non-vertebral fractures. Br J Rheumatol 1998;37:87-94
24. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41
25. Kanis JA, Borgström F, Johnell OOASD, et al. Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis Int 2005;16:15-25
26. Borgström F, Johnell O, Kanis JA, et al. Cost-effectiveness of raloxifene treatment of Osteoporosis in Sweden. Pharmacoeconomics 2004;22:1153-65
27. Stevenson M, Jones ML, DeNigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal Osteoporosis. Health Technology Assessment NHS R&D HTA Programme; 2005. Report No. 22, vol 1
28. Kanis JA, Brazier JE, Stevenson M, et al. Treatment of established Osteoporosis: a systematic review and cost-utility analysis. Health Technology Assessment NHS R&D HTA Programme; 2002. Report No. 6, vol 29
29. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with Osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. J Am Med Assoc 1999;282:637-45
30. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. J Am Med Assoc 2002;287:847-57
31. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 2001;65:125-34
32. Delmas P, Ensrud K, Adachi J, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with Osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-17
33. Papadimitropoulos EA, Coyte PC, Josse RG, et al. Current and projected rates of hip fracture in Canada. Can Med Assoc J 1997;157:1357-63
34. Kanis JA, Johnell O, Oden A, et al. Risk of hip fracture according to the World Health Organization criteria for osteopenia and Osteoporosis. Bone 2000;27:585-90
35. Black DM, Arden NK, Palermo L, et al. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures [Study of Osteoporotic Fractures Research Group]. J Bone Miner Res 1999;14:821-8
36. Riggs BL, Melton III LJ. Involutional Osteoporosis. New Engl J Med 1986;314:1676-86
37. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 1996;312:1254-9
38. [also selected for review in American College of Physicians Journal Club, 1996 September/October: 48. Br Med J 1996;312:1254-9]
39. Kannel WB, Wolf PA, Garrison RJ. The Framingham Study: an epidemiological investigation of cardiovascular disease. US Department of Health & Human Services 1987; NIH Publication 87-2284
40. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585-93
41. Statistics Canada CANSIM Database. Table 102-0525, deaths, by cause - chapter V: mental and behavioural disorders (F00-F99), age group and sex, Canada, annual. Available from: http://estat. statcan.ca/ 2005 May 18 [last accessed: 2005 July 15]
42. Statistics Canada CANSIM Database. Table 102-0540, deaths, by cause - chapter XX: external causes of morbidity and mortality (V01-Y89), age group and sex, Canada, annual. Available from: http://estat.statcan.ca/ 2005 May 18 [last accessed: 2005 July 15]
43. Wiktorowicz M, Goeree R, Papaioannou A, Adachi JD, Papadimitropoulos E. Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteo Int 2001;12(4):271-8
44. Kado DM, Browner WS, Palermo L, et al. Vertebral fractures and mortality in older women: a prospective study. Arch Intern Med 1999;159:1215-20
45. Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism. Arch Intern Med 1999;159:445-53
46. Ontario Ministry of Health. Ontario drug benefit formulary/comparative drug index. Available from: http://www.health.gov. on.ca/english/providers/ program/drugs/odbf_mn.html 2005
47. Ontario Ministry of Health and Long Term Care. Ontario health insurance plan (OHIP). Available from: http://www. health.gov.on.ca/english/public/ program/ohip/ohip_mn.html 2005. [last accessed: 2005 October 10]
48. The 1996 Pharmacy Business Trends Report. Toronto; 1998
49. Ontario Ministry of Health and Long Term Care. Schedule of benefits for physician services under the Health Insurance Act. 2005, Ottawa, Canada
50. Ontario Ministry of Health and Long Term Care. Ontario health insurance plan (OHIP) 2005. Available at: http://www. health.gov.on.ca/english/public/ program/ohip/ohip_mn.html). [accessed November 14, 2005]
51. Anon. Ontario case cost project (OCCP): Ontario guide to case costing, version 1.1. September ed. Ottawa: Ontario Case Cost Project; 1995
52. Ontario case costing initiative (OCCI). Available at: http://www.occp.com [accessed November 14, 2005]
53. Statistics Canada CANSIM Database. Table 326-0002, consumer price index (CPI), 2001 basket content, annual. Available from: http://estat.statcan.ca/ 2005 April 2 [last accessed 2005 September 13]
54. Will BP, Birthelot J, Houle C. A model for estimating the cost and burdens of breast cancer diagnosis and treatment in Canada. Health Reports 1993;5:399-408
55. Eli Lilly clinical study synopsis (study H3S-MC-GGGK). Comparison of raloxifene hydrochloride and placebo in the treatment of postmenopausal women with osteoporosis. Data on file 2000
56. Tosteson A, Gabriel S, Grove M, et al. Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporosis Int 2001;12:1042-9
57. Oldridge N, Guyatt G, Jones N, et al. Effects on quality of life with comprehensive rehabilitation after acute myocardial infarction. Am J Cardio 1991;67:1084-9
58. Nease RF, Kneeland T, O'Connor GT, et al. Variations in patient utilities for outcomes of the management of chronic stable angina. J Am Med Assoc 1995;273:1185-90
59. Hutton J, Brown R, Borowitz M, et al. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics 1996;9 (Suppl 2):8-22
60. Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Assoc 1997;4:49-56
61. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996
62. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Mak 1998;18(Suppl):S65-S80
63. Microsoft Office Online. Microsoft Excel, 2003. Available from: http://office.microsoft.com/ 2003 [last accessed: 2005 October 10]
64. TreeAge Pro, 2005. Available at: http://www.treeage.com/products/index. html
65. Statistics Canada. Life Expectancy. 2005. Available at: http://www40.statcan.ca/101/cst01/health26.htm
66. Drummond MF, Sculpher MJ, O'Brien BJ, et al. Methods for economic evaluation of health care programmes, 3rd ed. Oxford: Oxford University Press; 2005
67. Stavraky KM, Collins JA, Donner A, et al. A comparison of estrogen use by women with endometrial cancer, gynecologic disorder, and other illnesses. Am J Obstet Gynecol 1981;141: 547-55
68. LaVecchia C, Franceschi S, Decarli A, et al. Risk factors for endometrial cancer at different ages. J Natl Cancer Inst 1984;73:667-71
69. Shapiro S, Kelly J, Rosenberg L, et al. Risk of localized and widespread endometrial cancer in relation to recent and discounted use of conjugated estrogens. New Engl J Med 1985;313:969-72
70. Buring J, Bain C, Ehrmann R. Conjugated estrogen use and risk of endometrial cancer. Am J Epidemiol 1986;124:434-41
71. Ewertz M, Schou G, Boice J. The joint effect of risk factors on endometrial cancer. Eur J Cancer Clin Oncol 1988;24:189-94
72. Brinton L, Hoover R. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. Obstet Gynecol 1993;81:265-71
73. Jick SS, Walker AM, Jick H. Estrogens, progesterone, and endometrial cancer. Epidemiology 1993;4:20-4
74. Levi F, LaVecchia C., Gulie C, et al. Oestrogen replacement treatment and the risk of endometrial cancer: an assessment of the role of covariates. Eur J Cancer 1993;29:1445-9
75. Rubin G, Peterson H, Lee N, et al. Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies. Am J Obstet Gynecol 1990;162:148-54
76. Voigt L, Weiss N, Chu J, et al. Progestogen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274-7
77. Stampfer MJ, Colditz GA, Willett WC, et al. A prospective study of exogenous hormones and risk of endometrial cancer [abstract]. Am J Epidemiol 1986;124:520
78. Petitti D, Perlman J, Sidney S. Noncontraceptive estrogens and mortality: longterm follow-up of women in the Walnut Creek study. Obstet Gynecol 1987;70:289-92
79. Paganini-Hill A, Ross R, Henderson B. Endometrial cancer and patterns of use of estrogen replacement therapy: a cohort study. Br J Cancer 1989;59:445-7
80. Henderson B, Paganini-Hill A, Ross R. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75-8
81. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a metaanalysis. Obstet Gynecol 1995;85:1-10
82. Laupacis A, Feeny D, Detsky A, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1993;148:913-7